Publications de Ioanna Keklikoglou

Determinants of tumor resistance to anti-angiogenic immunotherapy in mouse models of Kras-mutant NSCLC

Ioanna Keklikoglou, Sina Nassiri, Etienne Meylan, Michele De Palma, Ece Kadioglu, Chiara Cianciaruso, Bruno Torchia, Alan Nicolas Thierry Guichard, Amaia Martinez Usatorre

AMER ASSOC CANCER RESEARCH2021

Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models

Ioanna Keklikoglou, Nadine Fournier, Sina Nassiri, Etienne Meylan, Michele De Palma, Ece Kadioglu, Chiara Cianciaruso, Bruno Torchia, Gael Luis Boivin, Alan Nicolas Thierry Guichard, Amaia Martinez Usatorre

Immune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of nonsmall cell lung cancer (NSCLC). However, only a minority of patients respond, and sustained remissions are rare. Both chemotherapy and antiangiogenic d ...

AMER ASSOC ADVANCEMENT SCIENCE2021

Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models

Ioanna Keklikoglou, Esra Güç, Michele De Palma, Mario Leonardo Squadrito, Antonino Cassarà, Chiara Cianciaruso, Alan Nicolas Thierry Guichard

Cytotoxic chemotherapy is an effective treatment for invasive breast cancer. However, experimental studies in mice also suggest that chemotherapy has pro-metastatic effects. Primary tumours release extracellular vesicles (EVs), including exosomes, that can ...

2019

Periostin Limits Tumor Response to VEGFA Inhibition

Ioanna Keklikoglou, Michele De Palma, Ece Kadioglu, Axel Bellotti

Resistance to antiangiogenic drugs limits their applicability in cancer therapy. Here, we show that revascularization and progression of pancreatic neuroendocrine tumors (PNETs) under extended vascular-endothelial growth factor A (VEGFA) blockade are depen ...

2018

Perivascular M2 macrophages stimulate tumor relapse after chemotherapy

Ioanna Keklikoglou, Michele De Palma

Tumor relapse after chemotherapy-induced regression is a major clinical problem, because it often involves inoperable metastatic disease. Tumor-associated macrophages (TAM) are known to limit the cytotoxic effects of chemotherapy in preclinical models of c ...

American Association for Cancer Research2015

Cancer: Metastasis risk after anti-macrophage therapy

Ioanna Keklikoglou, Michele De Palma

Nature Publishing Group2014

Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade

Ioanna Keklikoglou, Michele De Palma, Ece Kadioglu, Nicolo Rigamonti, Céline Wyser Rmili

Angiopoietin-2 (ANG2/ANGPT2) is a context-dependent TIE2 receptor agonist/antagonist and proangiogenic factor. Although ANG2 neutralization improves tumor angiogenesis and growth inhibition by vascular endothelial growth factor (VEGF)-A signaling blockade, ...

Elsevier2014